Dexamethasone and Restenosis After Coronary Stent Implantation: New Indication for an Old Drug?

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|10|4|349-355

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.10, Iss.4, 2004-02, pp. : 349-355

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A short course of sirolimus [rapamycin] substantially reduces the rate of restenosis after bare-metal coronary stent implantation

By  

Inpharma, Vol. 1, Iss. 1537, 2006-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Adjunct celecoxib beneficial after coronary drug-eluting stent implantation

By  

Inpharma, Vol. 1, Iss. 1602, 2007-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Comparison of Efficacy of Low- (80 mg/day) and High- (160-320 mg/day) Dose Valsartan in the Prevention of In-Stent Restenosis after Implantation of Bare-Metal Stents in Type B2/C Coronary Artery Lesions

By Peters Stefan  

American Journal of Cardiovascular Drugs, Vol. 8, Iss. 2, 2008-01 ,pp. : 83-87

Adis International

Access to resources Recommend Favorite

Pathobiology of Stent Thrombosis after Drug-Eluting Stent Implantation

By  

Current Pharmaceutical Design, Vol. 16, Iss. 36, 2010-12 ,pp. : 4064-4071

Bentham Science Publishers

Access to resources Recommend Favorite

Advances in Coronary Stent Technology - Active Drug-Loaded Stent Surfaces for Prevention of Restenosis and Improvement of Biocompatibility

By  

Current Pharmaceutical Biotechnology, Vol. 14, Iss. 1, 2013-01 ,pp. : 76-90

Bentham Science Publishers

Access to resources Recommend Favorite